A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer
- PMID: 6925983
- PMCID: PMC11039022
- DOI: 10.1007/BF00205385
A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer
Abstract
Two hundred and seventeen patients with advanced gastric cancer were classified according to the resectability of the tumour into two groups: I, resectable (non-radical surgery), 99 patients, and II, non-resectable carcinoma, 118 patients. Within each group patients were randomly assigned to receive 5-fluorouracil (5-FU) + BCG, 5-FU, or no further treatment (surgery only). BCG was given by scarification. A 2-year follow-up is reported. The group of patients with resectable tumours and receiving chemoimmunotherapy had a statistically significant prolongation of survival compared with the 5-FU and surgery only groups. No differences in survival were observed between these treatment modalities in patients with non-resectable tumour. These observations indicate that chemoimmunotherapy may be of benefit for a selected group of patients with gastric cancer.
References
-
- Ambus U, Falk RE, Landi S, Bugala R, Langer B. Randomized trials of chemoimmunotherapy for resectable and non-resectable gastrointestinal cancer. Dev Biol Stand. 1978;38:541. - PubMed
-
- Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin and mitomycin C (FAM) Cancer Treat Rep. 1979;63:2049. - PubMed
-
- Burdette WJ, Gehan EA. Planing and analysis of clinical studies. Springfield: Thomas; 1970. p. 72.
-
- Colton T. Statistics in medicine. Boston: Little Brown; 1974. p. 244.
-
- Clarysse A, Kenis Y, Mathé G. Cancer chemotherapy. Berlin Heidelberg New York: Springer; 1976. p. 424.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical